Urgent

Lupus nephritis (SLE glomerulonephritis, ISN/RPS class I-VI)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Renal involvement in systemic lupus erythematosus, a major driver of SLE morbidity/mortality. Immune-complex glomerulonephritis classified ISN/RPS class I-VI; class III (focal) and IV (diffuse) proliferative disease (and mixed +/- class V membranous) are the aggressive forms requiring prompt immunosuppression, while class V is membranous-pattern nephrotic. Presents with haematuria, proteinuria, hypertension, active sediment, declining GFR and low complement (C3 AND C4) with high anti-dsDNA. Early biopsy-guided therapy preserves kidney function.

Red flags

  • Rapidly rising creatinine with active sediment/crescents — aggressive proliferative/crescentic LN, urgent immunosuppression
  • Nephritic-nephrotic with hypertension and falling GFR
  • Thrombotic microangiopathy features (thrombocytopenia, MAHA) — APS nephropathy or TTP/HUS overlap
  • Pulmonary haemorrhage, cerebral lupus, severe cytopenias — life-threatening multisystem flare
  • Pregnancy with active lupus nephritis — high-risk, specialist multidisciplinary care

Assessment

Differential diagnosis

  • Other proliferative/immune-complex GN (post-infectious, MPGN, IgA)
  • ANCA vasculitis / anti-GBM (pauci-immune RPGN)
  • Thrombotic microangiopathy (antiphospholipid syndrome nephropathy, TTP/HUS) — may coexist with lupus
  • Primary membranous nephropathy (vs lupus class V)
  • Drug-induced lupus; chronic kidney disease of other cause

Investigations

  • Urine microscopy (dysmorphic RBCs, red/cellular casts) + PCR/ACR; serum albumin, U&E/creatinine/eGFR, BP
  • SLE serology: ANA, anti-dsDNA (correlates with renal activity), complement C3 and C4 (both low in active disease), anti-Sm, ENA
  • Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2GPI) — APS nephropathy risk
  • FBC (cytopenias), haemolysis screen/blood film (coexistent TMA), CRP/ESR
  • Renal biopsy — essential to assign ISN/RPS class, activity and chronicity indices (directs therapy)
  • Baseline for immunosuppression: HBV/HCV/HIV, TB screen, pregnancy test, thiopurine methyltransferase (if azathioprine planned)

Management

  • Diagnose SLE and perform early renal biopsy to classify (class and activity/chronicity) — this governs treatment intensity
  • All patients: hydroxychloroquine (improves renal and overall outcomes), BP control and RAS blockade for proteinuria, statin, sun protection, bone/infection prophylaxis
  • Class I/II (minimal/mesangial): treat extrarenal lupus; renoprotection, no intensive renal immunosuppression
  • Active class III/IV (+/- V) proliferative disease: start initial immunosuppression with glucocorticoids PLUS either mycophenolate (MMF/MPA analogue) or low-dose IV cyclophosphamide (Euro-Lupus), and add a second agent as triple therapy — belimumab or a calcineurin inhibitor (voclosporin/tacrolimus) — per KDIGO 2024
  • Use glucocorticoid-sparing strategy: pulse IV methylprednisolone then a RAPID oral prednisolone taper to minimise steroid toxicity
  • Pure class V (membranous): immunosuppression if nephrotic/progressive, with anticoagulation considerations as for membranous nephropathy
  • Maintenance (>=3 years): mycophenolate or azathioprine (azathioprine if pregnancy planned) +/- belimumab, continuing hydroxychloroquine; monitor dsDNA/complement, proteinuria and eGFR for flares
  • Manage APS/thrombosis, pregnancy planning (teratogen avoidance: MMF/cyclophosphamide/ACEi), and infection prophylaxis (PCP) throughout

Drugs & doses

Hydroxychloroquine 200-400 mg PO once daily (max ~5 mg/kg/day; baseline + annual ophthalmology) — for essentially all SLE
Pulse methylprednisolone 250-500 mg (up to 1 g) IV daily x3 then oral prednisolone with rapid taper (KDIGO 2024 low-dose approach) [verify local dose]
Mycophenolate mofetil 1-1.5 g PO twice daily (target ~2-3 g/day) for induction and maintenance [verify local dose]
Low-dose IV cyclophosphamide (Euro-Lupus): 500 mg IV every 2 weeks x6 doses as an alternative induction [verify local dose]
Voclosporin 23.7 mg PO twice daily (added to MMF + steroid as triple therapy) [verify local dose]
Belimumab 10 mg/kg IV (or 200 mg SC weekly) added to standard therapy [verify local dose]
Azathioprine 1.5-2.5 mg/kg/day PO for maintenance (preferred if pregnancy planned; check TPMT) [verify local dose]
Ramipril/losartan for proteinuria + BP; co-trimoxazole PCP prophylaxis during intensive immunosuppression [verify local dose]

Disposition

Admit for significant AKI, severe/crescentic nephritis, major multisystem flare or new diagnosis needing urgent biopsy and induction. Co-manage with nephrology and rheumatology; long-term maintenance and monitoring outpatient. Pregnancy and APS need specialist MDT input.

Complications & pitfalls

  • Progression to ESKD; flares and chronic proteinuric CKD
  • Immunosuppression/steroid toxicity: infection, osteoporosis, avascular necrosis, gonadotoxicity (cyclophosphamide), malignancy
  • Thromboembolism (antiphospholipid syndrome)
  • Accelerated cardiovascular disease
  • Adverse pregnancy outcomes; teratogenicity of several agents

Exam pearls

  • Low C3 AND low C4 with high anti-dsDNA points strongly to lupus nephritis (vs post-strep where only C3 falls) — but the biopsy class, activity and chronicity still decide therapy.
  • KDIGO 2024 favours TRIPLE therapy for active class III/IV: steroid + mycophenolate (or low-dose cyclophosphamide) PLUS belimumab or voclosporin, with a rapid steroid taper to cut toxicity.
  • Hydroxychloroquine is for almost every lupus patient — it improves renal outcomes and reduces flares; do not omit it.
  • Switch mycophenolate to azathioprine before a planned pregnancy and stop ACEi/ARB — MMF, cyclophosphamide and RAS blockers are teratogenic.
  • Euro-Lupus low-dose IV cyclophosphamide (500 mg x6) is as effective as high-dose with far less toxicity.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.